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Background. Oral direct-acting antivirals (DAAs) provide an exceptional opportunity to treat hepatitis C virus (HCV) infection.
Goals. We compared the treatment outcomes between specialty and primary care physician (PCP) clinics for patients treated
with DAAs. Methods. We performed a retrospective analysis of patients treated for HCV in our PCP clinics and specialty; liver
and gastroenterology clinics and gastroenterology clinics. We used the two-sided t-test and the chi-square test to compare the
means of continuous and categorical variables, respectively. Results. Data from a total of 377 patients was analyzed (PCP clinic:
n = 185 and specialty clinic: n = 192). There was no signiﬁcant diﬀerence between age, race, and gender. Model for End-Stage
Liver Disease (MELD) and Child-Turcotte-Pugh (CTP) scores were comparable at baseline. Greater than 90% of the patients
achieved sustained virological response (SVR) with no diﬀerence between the groups. Conclusions. Uncomplicated patients can
be treated for hepatitis C by their PCPs with DAAs with similar treatment outcomes to specialty clinics. There should be explicit
guidelines on patient eligibility for treatment by PCPs vs. specialists.

1. Introduction
Novel oral direct-acting antivirals (DAAs) have completely
changed the spectrum of hepatitis C treatment with multiple
studies showing sustained virological response (SVR) of over
90% for many genotypes [1–3]. Approximately 3.5 million
people in the USA are infected with HCV [4]. Since the introduction of DAAs in the late 2013, almost 350,000 patients in
the USA have been treated with these agents. This is a small
portion of the HCV-infected population which leaves a huge

number of treatment-naïve patients who can beneﬁt from
this cost-eﬀective treatment [5, 6]. The outpatient setting
has always focused on screening, diagnosis, and referring
patients for appropriate treatment through specialists including gastroenterologists and hepatologists [7, 8]. There has
always been some amount of uneasiness among primary care
physicians (general internal medicine and family medicine)
[9] for the management of important aspects of HCVrelated healthcare [10–12]. Over the last few years, trends
have changed from a merely screening-and-referral strategy
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to a more self-initiated treatment of HCV infection by primary care physicians (PCPs) themselves [13]. One reason
for this shifting paradigm was Project ECHO (Extension for
Community Healthcare Outcomes), which was launched in
2003 in Mexico and ampliﬁed the capacity to practice the
best medicine in underdeveloped and rural areas through
telemedicine including video conferencing. The purpose of
this was to enhance capabilities of PCPs for complex patient
care in underserved communities [14]. A subsequent study
published by Arora et al. in New England Journal of Medicine
in 2011 showed that the quality of hepatitis C treatment
received by physicians trained through the program ECHO
was comparable to specialist’s level care [15]. This ECHO
act was approved by the US in the late 2016. A similar study
recently published in April 2017 used the project ECHO to
the VA population (VA-ECHO) [16]. The results were
promising and showed that telemedicine through Project
ECHO can increase awareness about hepatitis C treatment
initiation especially in Veterans Aﬀairs (VA) hospitals in
far rural areas. The ECHO project is cost-eﬀective and
stresses the fact that chronic HCV infection burden in the
US can be reduced by increasing awareness of hepatitis C
treatment in the primary care setting [17–19]. The successful
implementation of this project in multiple states has proven
the utility of PCPs to treat HCV infection through expanding
their educational capacity and increasing their comfortability
level [15, 20]. The purpose of our study was to assess outcomes of PCPs treating HCV-infected US veterans with
DAAs after the incorporation of educational initiatives and
collaborations with specialists.

to patients treated in the specialty clinic. We collected the
baseline characteristics (age, gender, race, smoking history,
alcohol history, and HCV genotype), baseline HCV RNA
level, achievement of SVR, coinfection with hepatitis B or
HIV, hepatocellular carcinoma (HCC) development after
starting treatment, Model of End Stage Liver Disease
(MELD) scores, Child-Turcotte-Pugh (CTP) scores, and
other cirrhosis-related pre- and posttreatment laboratory
parameters.

2. Methods

3. Results

We performed a retrospective chart review to identify
patients treated for HCV from January 2014 to May 2017,
at our PCP clinics and specialty; liver and gastroenterology
clinics. The departments of internal medicine, gastroenterology, hepatology, and pharmacy got together to establish a
multidisciplinary approach to deal with the shortage of physicians available to treat hepatitis C patients in the DAA era
as many of them who were not considered for treatment in
the interferon era were now eligible for treatment with
DAAs. We had two educational sessions conducted by
hepatologists for PCPs on chronic HCV management with
DAAs. Afterwards, the PCPs had full support of the pharmacy department in monitoring and dispensing of these
medications.
After this intervention and from May 2016 onwards, it
was decided to send noncirrhotics to PCP clinics for treatment whereas the specialty clinic was still treating both cirrhotics and noncirrhotics in addition to patients who had
coinfection with hepatitis B virus (HBV) and HCV, were
human immunodeﬁciency virus (HIV) infected, had ribavirin in the treatment regimen, or had prior treatment failure.

In total, the data from 673 HCV-infected patients was
extracted. 488 patients were treated in the specialty clinic
and 185 in the PCP clinic (Figure 1). The rate of SVR was
high in the PCP clinic as compared to specialty clinic
(93.51 vs. 92.40, p = 0 62). Since cirrhotics were being treated
in the specialty clinic, they were excluded to prevent any bias,
since cirrhosis is an independent risk factor for poor treatment outcomes (decreased SVR rates) [21]. Data from a total
of 377 patients was reanalyzed. 192 and 185 noncirrhotics
(via biochemical and radiological studies) were treated in
the specialty and PCP clinics, respectively. Compliance to
medication was noted by regular visits at the time of enrollment, four weeks into treatment (4VR), end of treatment
(ETR), and SVR lab withdrawal. Demographic variables are
presented in Table 1, and clinical outcomes assessed by the
chi-square or t-test are presented in Table 2. The groups were
comparable in regard to race, gender, MELD, CTP, FIB-4
scores, and posttreatment labs (AST, ALT, hemoglobin, total
bilirubin, albumin, and sodium) (Table 2). All patients in
both groups completed therapy. The HCV genotype was
known for all patients; 112 (58.33%) specialty clinic and
113 (61.08%) PCP clinic patients had genotype 1a, which
was the most common genotype. SVR was achieved in more
than 90% of the patients in both groups separately, and there
was no statistical diﬀerence for SVR results between the
groups (Table 2). The risk diﬀerence of the proportions of

2.1. Study Population. A total number of 731 HCV-infected
patients were treated by 62 primary care and 5 specialty physicians at our Veterans Aﬀairs Medical Center. Clinical outcomes of patients treated in the PCP clinic were compared

2.2. Inclusion Criteria. Adults, both men and women,
between ages 18-79 years, were included in the study. These
patients were infected with HCV and received treatment in
their PCP or specialty clinic.
2.3. Exclusion Criteria. Patients with loss to follow-up due to
transfer of care to another facility, death before SVR, or no
show for SVR labs were not included as per protocol.
2.4. Statistical Analysis. We used the two-sided t-test and the
chi-square test to compare the means of continuous and
categorical variables, respectively. The analysis was performed with the statistical analysis software (SAS). A p value
of <0.05 was considered statistically signiﬁcant. The 95%
conﬁdence interval was calculated using a Wald asymptotic
95% conﬁdence interval for diﬀerence of two proportions.
2.5. Main Outcome Measure. The primary endpoint was SVR
(an undetectable HCV viral load 12-week posttreatment),
which represents cure. Development of HCC was our
secondary endpoint.
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Total # of patients treated
= 731
# of patients treated in PCP
clinic = 215

# of patients treated in liver
clinic = 516
Loss to follow-up
(i) Did not show for SVR
labs = 22

Loss to follow-up
(i) Did not show for SVR
labs = 17
(ii) Died before SVR = 4
(reason of death)

(ii) Died before SVR = 1
(reason of death)

(iii) Moved to another state
before SVR = 9

# of remaining
patients = 488
# of remaining patients (all
noncirrhotics) = 185

(iii) Moved to another state
before SVR = 5

296 # of cirrhotic patients
completed treatment

# of noncirrhotic patients
completed treatment = 192

Figure 1: Flow chart.

Table 1: Demographic values by clinic with the chi-square test or the t-test.
Demographic variables

GI clinic (n = 192)

PCP clinic (n = 185)

p value

Age, average (range)
Male sex, n (%)
Race, n (%)
(a) Caucasian
(b) African American
(c) Other∗

60.71 (29-78)
180 (94.74%)

61.54 (30-87)
182 (98.38%)

0.27
0.05

130 (73.00%)
42 (23.60%)

114 (64.41%)
55 (31.07%)

0.22

(d) Unknown
Cirrhosis, n (%)
Comorbidities
(a) CHF, n (%)
(b) HTH, n (%)
History of the previous alcohol use, n (%)
History of the previous smoking, n (%)
History of the previous IVDU, n (%)

6 (3.37%)

8 (4.52%)

14 (7.29%)
0 (0.0%)

8 (4.52%)
0 (0.0%)

5 (2.63%)
123 (64.40%)
178 (94.68%)
133 (70.74%)
115 (61.17%)

12 (6.52%)
123 (66.85%)
109 (62.29%)
48 (29.09%)
46 (27.38%)

0.07
0.62
<0.01
<0.01
<0.01

∗
Other: Native American and Asian. Abbreviations: GI: gastroenterology; PCP: primary care physician; CHF: congestive heart failure; HTN: hypertension;
IVDU: intravenous drug use.

patients achieving SVR in both groups (95.8% in the GI clinic
and 93.5% in the PCP clinic) was 2.32% with 95% CI of
-2.05% to 6.69%. The number of treatment-naïve patients
was higher in the PCP clinic as compared to GI clinic
(92.97% vs. 77.60%, p = <0 01) (Table 3). The top three drugs
used in the PCP clinic were Harvoni, Epclusa, and Zepatier
whereas in the GI clinic, Harvoni, sofosbuvir/ribavirin, and
Viekira/ribavirin were more often used. 97.56% and 93.06%
of patients achieving SVR in the GI and PCP clinics, respectively, received Harvoni as sole treatment (Table 4). Most
patients achieving SVR were genotype 1a in both groups
(96.4% in the GI clinic vs. 92.92% in the PCP clinic)
(Table 5). MELD, CTP, and FIB-4 scores were comparable
at SVR. No major complications such as death were reported.
Only two patients developed HCC, one from each group.
There was no diﬀerence in markers of disease severity posttherapy, assessed by MELD, CTP, and FIB-4 scores
(Table 2). As far as high-risk behavior was concerned, history
of smoking, alcohol intake, and IVDU was more common in
patients treated in the GI clinic (p < 0 01).

4. Discussion
HCV infection has always been a prevalent but less diagnosed
viral infection. The reason is the knowledge gap and lack
of educational expertise outside of the specialist practice
[7, 22]. However, treatment of hepatitis C by a PCP results
in less loss to follow-up due to familiarity with patient
social dynamics prior to HCV treatment initiation. Treating
HCV infection themselves increases their awareness of liver
diseases and is a source of intellectual satisfaction that can
prevent burn out as well [23]. Contrary to this, PCPs have
to face certain drawbacks. PCPs have to treat patients in
entirety and thus put a knowledge burden on them. HCV
treatment is often restricted by payers to patients with
advanced ﬁbrosis forcing PCPs to perform additional tests
like a ﬁbroscan that requires another complex level of understanding [24, 25]. Time restraints, knowledge gaps, easy
access to the specialty referral, apprehension of medicolegal
litigation, lack of HCV treatment in PCP quality measures,
and provider restrictions on the prescription of independent

7.32 (6.96-7.68)
5.08 (5.03-5.13)
1.83 (1.71-1.95)
56.41 (50.04-62.79)
45.97 (42.04-49.91)
14.86 (14.66-15.06)
0.80 (0.75-0.84)
4.03 (3.98-4.07)
138.1 (137.8-138.5)

Patients achieving SVR, n (%)
MELD score, mean (range)
CTP score, mean (range)
Fib-4 score, mean (range)
ALT, mean (range)
AST, mean (range)
Hemoglobin, mean (range)
T. bilirubin, mean (range)
Albumin, mean (range)
Na, mean (range)
Reported HCC posttherapy, n (%)
7.87 (7.39-8.34)
5.14 (5.09-5.20)
1.96 (1.84-2.07)
49.55 (44.51-54.60)
45.51 (42.16-48.87)
14.84 (14.60-1t5.08)
0.75 (0.70-0.79)
3.91 (3.85-3.97)
136.9 (136.5-137.4)

PCP clinic (n = 185)
before SVR
0.27
0.08
0.14
0.10
0.86
0.91
0.10
<0.01
<0.01

Parametric p value∗
184 (95.83%)
8.50 (6.00-26.00)
5.39 (5.00-11.00)
1.80 (0.53-13.14)
21.87 (6.00-60.00)
25.87 (14.00-83.00)
14.71 (8.30-17.80)
0.71 (0.20-4.60)
3.99 (1.21-5.00)
137.7 (128.0-143.0)
1 (0.52%)

GI clinic (n = 192)
at SVR

173 (93.51%)
8.41 (6.00-24.00)
5.22 (5.00-8.00)
1.63 (0.69-5.18)
22.99 (7.00-173.00)
27.29 (10.00-89.00)
14.65 (10.90-18.70)
0.65 (0.10-2.30)
4.00 (0.30-4.90)
137.2 (127.0-143.0)
1 (0.54%)

PCP clinic (n = 185)
at SVR

0.32
0.93
0.44
0.19
0.44
0.25
0.75
0.18
0.98
0.08
1.00

Parametric
p value∗

Abbreviations: GI: gastroenterology; PCP: primary care physician; SVR: sustained virological response; MELD: Model for End-Stage Liver Disease; CTP: Child-Turcotte-Pugh; AST: aspartate aminotransferase;
ALT: alanine aminotransferase; HCC: hepatocellular carcinoma.

GI clinic (n = 192)
before SVR

Covariate

Table 2: Outcomes by clinic with the chi-square test or t-test.

4
Gastroenterology Research and Practice

Gastroenterology Research and Practice

5

Table 3: Prior hepatitis C treatment regimens for patients treated in GI vs. PCP clinic.
Prior treatment

GI clinic (noncirrhotic) Group-1 (n = 192)

PCP clinic (noncirrhotic) Group-2 (n = 185)

p value

149 (77.60)
43 (22.40)
33 (17.19)
5 (2.60)
4 (2.08)
0
1 (0.52)

172 (92.97)
13 (7.03)
11 (5.95)
1 (0.54)
0
1 (0.54)
0

<0.01

Treatment naïve, n (%)
Previous treatment, n (%)
Interferon+ribavirin
PEG/ribavirin/boceprevir
Harvoni & ribavirin
Viekira Pak+ribavirin
Interferon

<0.01

Abbreviations: GI: gastroenterology; PCP: primary care physician; PEG: pegylated interferon alpha.

Table 4: SVR outcomes based on the prescribed anti-HCV medication.
Current treatment
Harvoni
Sofosbuvir+ribavirin
Epclusa
Viekira+ribavirin
Zepatier
Harvoni+ribavirin
Sofosbuvir+Harvoni
Sofosbuvir+simeprevir
Daklinza+sofosbuvir
Sofosbuvir+ribavirin+IFN
Ledipasvir/sofosbuvir
Viekira
Technivie/ribavirin
Harvoni/Viekira/Zepatier

GI clinic
(noncirrhotic)
Group-1 (n = 192)

PCP clinic
(noncirrhotic)
Group-2 (n = 185)

123 (64.06)
33 (17.19)
0
17 (8.85)
0
9 (4.69)
3 (1.56)
1 (0.52)
1 (0.52)
1 (0.52)
1 (0.52)
1 (0.52)
1 (0.52)
1 (0.52)

144 (77.84)
0
25 (13.51)
0
15 (8.11)
1 (0.54)
0
0
0
0
0
0
0
0

p value
<0.01

n (%) of patients achieving n (%) of patients achieving
SVR in PCP clinic for
SVR in GI clinic for
the drug
the drug
120 (97.56)
32 (96.97)
0
15 (88.24)
0
7 (77.78)
3 (100)
1 (100)
1 (100)
1 (100)
1 (100)
1 (100)
1 (100)
1 (100)

134 (93.06)
0
24 (96.00)
0
14 (93.33)
1 (100)
0
0
0
0
0
0
0
0

Abbreviations: GI: gastroenterology; PCP: primary care physician; SVR: sustained virological response; IFN: interferon.

HCV treatment are some of the reasons why PCPs are not
comfortable treating hepatitis C [23, 26, 27]. Deﬁnitely, voluntary participation by PCPs is still the key factor here.
There have been no guidelines on when HCV-infected
patients should be referred to the PCP clinic. In our institution, we established our own referral criteria that focused
on complex patients being treated in the specialty clinic.
The updated guidelines are written by specialists for specialists and are not intended for the PCP audience. When it
comes to referral to the specialty clinic, there are no clear
indications when PCP should refer to specialists rather than
treating themselves [28]. Our study found that HCVinfected patients with mild disease as assessed by MELD
score, CTP score, and FIB-4 score can be treated successfully
by PCPs with comparable SVR to the specialty clinics. As far
as referral is concerned, guidelines based on ﬁrm evidence
and extensive research with clear-cut indications on when
to request a specialist referral should be outlined.
Finally, the elimination of hepatitis C is a public health
goal and to achieve, it will require a multidisciplinary
approach with hepatitis C treatment awareness and access

to multiple health care workers in health care settings including PCP clinics, pharmacist clinics, methadone clinics, and
prisons. In our clinics, pharmacists played a role of a clinical
and specialty pharmacist and as such, assisted physicians in
prior medication authorization, prescription fulﬁllment,
and patient telephonic counseling. On the other hand, a
health system specialty pharmacist can be directly involved
in hepatitis C treatment initiation further reducing the burden of hepatitis C management that has shown promising
results [29, 30]. Since diﬀerent DAAs are selected based on
their pharmacodynamics, adverse eﬀects, eﬃcacy, cost implications, and insurance approval, the role of pharmacists can
be promising to enhance treatment access. By the participation of PCPs and pharmacists, the WHO goals for viral
hepatitis can be achieved.
4.1. Study Limitations. There are several limitations to this
study. This study took place in diﬀerent clinics (PCP vs.
GI) but in one hospital setting. Thus, these ﬁndings may
not be generalizable to all settings. We did not directly study
the parameters for nonadherence rather considered SVR to
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Table 5: SVR outcomes based on the hepatitis C genotype.

Hepatitis C
genotype

GI clinic (noncirrhotic) PCP clinic (noncirrhotic)
p value
Group-1 (n = 192)
Group-2 (n = 185)

1a, n (%)
1b, n (%)
2b, n (%)
2, n (%)
4, n (%)
3a, n (%)
1, n (%)
2a/2c, n (%)
3, n (%)
1a/1b, n (%)
2b & 3, n (%)
4a/4c/4d, n (%)

112 (58.33)
32 (16.67)
25 (13.02)
8 (4.17)
4 (2.08)
3 (1.56)
3 (1.56)
2 (1.04)
2 (1.04)
1 (0.52)
0
0

113 (61.08)
50 (27.03)
12 (6.49)
1 (0.54)
0
3 (1.62)
0
2 (1.08)
0
2 (1.08)
1 (0.54)
1 (0.54)

n (%) of patients achieving n (%) of patients achieving
SVR in GI clinic for
SVR in PCP clinic for
the genotype
the genotype

<0.01

108 (96.43)
31 (96.88)
25 (100)
8 (100)
4 (100)
2 (66.67)
2 (66.67)
2 (100)
1 (50.00)
1 (100)
0
0

105 (92.92)
47 (94.00)
11 (91.67)
1 (100)
0
3 (100)
0
2 (100)
0
2 (100)
1 (100)
1 (100)

Abbreviations: GI: gastroenterology; PCP: primary care physician; SVR: sustained virological response.

be a marker of adherence to the treatment regimen. As
compared to PCP clinics, the specialty clinics treated more
complicated patients with past high-risk lifestyle habits
including smoking, alcohol intake, and intravenous drug
use. These lifestyle diﬀerences might be a potential cause
of confounding.

5. Conclusions
HCV patients with mild disease severity who were treated in
the PCP clinics achieved SVR at rates comparable to HCV
patients treated in the specialty clinics. This high SVR was
achieved through a multidisciplinary approach including
PCPs. Uncomplicated patients can be treated for hepatitis C
by their PCPs with safe and cost-eﬀective DAAs and thereby
relieve the heavy burden on the specialty clinics especially in
Veterans Aﬀairs (VA) Health which is considered to be the
world’s largest hepatitis C care provider. However, further
educational initiatives and explicit practice guidelines for
PCPs are needed.
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